Rigerna

Suzhou Rigerna Therapeutics and Beijing Rigerna Rui Pharmaceutical Technology Co., Ltd. (Rigerna) were established in 2022. The company focuses on the research and industrialization of innovative small nucleic acid drugs, rooted in China while targeting the global market (In China, For Global), with the ambition to become a leader and innovator in the field of nucleic acid pharmaceuticals. The company has gathered a core team with over 10 years of industry experience, possessing extensive expertise in nucleic acid biology, nucleic acid chemistry, liver and non-liver delivery, project management, pharmaceutical research, regulatory submissions, and clinical development. Rigerna has developed proprietary global intellectual property platforms such as RIHOST®, RICMO®, and LICOD® to address key technological bottlenecks, intellectual property barriers, and future directions in this field. Multiple in vivo delivery technologies for non-liver tissues have been established based on several exclusive strategies. Additionally, the company demonstrates profound understanding and differentiated considerations in target and indication selection. Liver-targeting products are about to enter clinical studies, and the rapid advancement of a series of innovative nucleic acid drugs for non-liver tissues will bring benefits to patients.